Claybrook Capital’s Novartis NVS Stock Holding History

Claybrook Capital’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-15,463	Closed	-$1.41M	–	207
2021 Q2	$1.41M	Buy	+15,463	New	+$1.38M	0.46%	66
2019 Q1	–	Sell	-80	Closed	-$6K	–	489
2018 Q4	$6K	Buy	+80	New	+$6.23K	﹤0.01%	553
2018 Q1	–	Sell	-307	Closed	-$23K	–	201
2017 Q4	$23K	Buy	+307	New	+$23.2K	0.02%	136

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Aristotle Capital Management Los Angeles, California $47.8B AUM 13.38% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Claybrook Capital's NVS Position: Q3 2021 in Review

Claybrook Capital sold out of Novartis (NVS) in Q3 2021, closing a stake of 15,463 shares — an estimated $1.41M sold.

Claybrook Capital first reported a position in NVS in Q4 2017 and held it in 3 quarters. The position peaked at $1.41M in Q2 2021. 1,080 funds tracked by Wall St. Rank hold NVS as of Q3 2021.

Claybrook Capital reported no remaining Novartis position as of Q3 2021 after selling out during the quarter.
Claybrook Capital sold 15,463 Novartis shares in Q3 2021, an estimated $1.41M.
Claybrook Capital first reported a position in Novartis in Q4 2017 and held it in 3 quarters.
Claybrook Capital's Novartis position peaked at $1.41M in Q2 2021.
1,080 funds tracked by Wall St. Rank held Novartis as of Q3 2021.

Based on Claybrook Capital's 13F filing for Q3 2021, filed 15 Nov 2021.